Filing Flows › Davita (DVA) › Q2 2026 › vs Q2 2025
Davita (DVA) Q2 2026 vs Q2 2025 (year over year)
Davita's revenue rose $175M (+5%) from $3.4B in Q2 2025 to $3.6B in Q2 2026. The biggest changes: U. S. Dialysis and Related Lab Services +$104M (+4%); Other - Ancillary Services +$70.8M (+15%). Operating margin 16.3% against 15.9% (+0.4 pts).
Davita, Q2 2026: revenue $3.6B (+5% year over year), operating margin 16.3%, net earnings $265M, operating cash flow $490M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 16.3% | 15.9% | +0.4 pts |
| Net margin | 7.5% | 5.9% | +1.6 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| U. S. Dialysis and Related Lab Services | $3.0B | $2.9B | $104M | +4% |
| Other - Ancillary Services | $554M | $483M | $70.8M | +15% |
| Revenue | $3.6B | $3.4B | $175M | +5% |
| Operating profit | $579M | $538M | $41.2M | +8% |
| Costs & expenses | $3.0B | $2.8B | $133M | +5% |
| Pre-tax earnings | $435M | $369M | $66.1M | +18% |
| Other expense, net | $144M | $169M | −$24.9M | -15% |
| General & admin | $423M | $413M | $10.7M | +3% |
| Other operating costs | $2.6B | $2.4B | $123M | +5% |
| Net earnings | $265M | $199M | $66.1M | +33% |
| Minority interests | $77.8M | $75.9M | $1.9M | +3% |
| Income tax | $91.8M | $93.7M | −$1.9M | -2% |
| Depreciation & amortization | $168M | $175M | −$6.9M | -4% |
| Share-based compensation | $26.0M | $32.8M | −$6.8M | -21% |
| Working capital & other | $30.8M | −$82.6M | $113M | — |
| Operating cash flow | $490M | $324M | $166M | +51% |
Questions
How much did Davita's revenue grow year over year in Q2 2026?
Davita's revenue rose $175M (+5%) from $3.4B in Q2 2025 to $3.6B in Q2 2026.
What drove Davita's revenue change in Q2 2026?
U.